Hepatic Involvement as Hyperbilirubinemia in Patients with COVID-19: Case Series from Iran

Title:Hepatic Involvement as Hyperbilirubinemia in Patients with COVID-19: Case Series from Iran

Volume: 21 Issue: 8

Author(s): Ahmad Hormati, Mohammad Reza Ghadir, Mohammad Saeidi, Reza Aminnejad, Mahboubeh Afifian and Sajjad Ahmadpour*

Affiliation:

• Assistant Professor of Nuclear Pharmacy, Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, ,Iran

Keywords: COVID-19, rRT-PCR, hyperbilirubinemia, CT, scan, gastrointestinal, symptom, GI enzyme.

Abstract: Background: After the spread of novel coronavirus disease 2019 (COVID-19) from Wuhan to Iran, gastroenterology clinics, was faced with a large number of patients who were suspected of being infected with the SARS-CoV-2. Among refereed patient, the incidence of pure hyperbilirubinemia as rare gastrointestinal (GI) symptoms was obvious.

Methods: In this case series, we have reported the clinical data in details for patients with COVID-19 who have been admitted to the Shahid Beheshti Hospital in Qom city, from 3 March to 3 August 2020. COVID infection, be confirmed by using real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) and chest computed tomography (CT) scan, as well.

Results: According to the clinical findings, pure hyperbilirubinemia may consider as rare gastrointestinal (GI) symptom of COVID-19. However, it is possible that the other GI enzymes values fall in to the normal range.

Conclusion: In some infected patients, GI physicians may face hepatic involvement as pure hyperbilirubinemia. At the age of COVID-19 crisis, all GI physicians should be aware of the possible occurrence of hepatic involvement as an important prognosis of COVID pneumonia and it should be exactly addressed in new referred patients to GI clinic.

Cite this article as:

Hormati Ahmad , Ghadir Reza Mohammad , Saeidi Mohammad , Aminnejad Reza , Afifian Mahboubeh and Ahmadpour Sajjad *, Hepatic Involvement as Hyperbilirubinemia in Patients with COVID-19: Case Series from Iran, Infectious Disorders - Drug Targets 2021; 21 (8) : e160921191569 . https://dx.doi.org/10.2174/1871526521666210218201601